Cancer research and Breast cancer are two areas of study in which Dan G. Duda engages in interdisciplinary work. Dan G. Duda undertakes interdisciplinary study in the fields of Cancer and Obesity through his works. He regularly links together related areas like Endocrinology in his Obesity studies. In his articles, Dan G. Duda combines various disciplines, including Endocrinology and Oncology. He performs multidisciplinary study in the fields of Oncology and Cancer research via his papers. His Myeloid research extends to the thematically linked field of Internal medicine. As part of his studies on Pancreatic cancer, he often connects relevant areas like Desmoplasia. His research on Desmoplasia often connects related areas such as Pancreatic cancer. His study in Receptor extends to Fibroblast growth factor with its themes.
As part of his inquiry into Neovascularization and Angiogenesis inhibitor, Dan G. Duda is doing Angiogenesis research. Dan G. Duda merges Angiogenesis inhibitor with Angiogenesis in his study. Dan G. Duda performs integrative Cancer research and Metastasis research in his work. In his articles, he combines various disciplines, including Genetics and Genetic enhancement. In his works, Dan G. Duda undertakes multidisciplinary study on Cancer and Metastasis. Dan G. Duda conducted interdisciplinary study in his works that combined Internal medicine and Endocrinology. He carries out multidisciplinary research, doing studies in Endocrinology and Internal medicine. He undertakes multidisciplinary investigations into Gene and Genetic enhancement in his work. His Biochemistry study frequently draws connections between adjacent fields such as Mutant.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
Christopher G Willett;Yves Boucher;Emmanuelle di Tomaso;Dan G Duda.
Nature Medicine (2004)
AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients
Tracy T. Batchelor;A. Gregory Sorensen;A. Gregory Sorensen;Emmanuelle di Tomaso;Wei Ting Zhang;Wei Ting Zhang.
Cancer Cell (2007)
NORMALIZATION OF THE VASCULATURE FOR TREATMENT OF CANCER AND OTHER DISEASES
Shom Goel;Dan G. Duda;Lei Xu;Lance L. Munn.
Physiological Reviews (2011)
Angiogenesis in brain tumours
Rakesh K. Jain;Emmanuelle di Tomaso;Dan G. Duda;Jay S. Loeffler.
Nature Reviews Neuroscience (2007)
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Rakesh K Jain;Dan G Duda;Jeffrey W Clark;Jay S Loeffler.
Nature Reviews Clinical Oncology (2006)
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
Dai Fukumura;Jonas Kloepper;Zohreh Amoozgar;Dan G. Duda.
Nature Reviews Clinical Oncology (2018)
Engineering vascularized tissue
Rakesh K Jain;Patrick Au;Josh Tam;Dan G Duda.
Nature Biotechnology (2005)
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
Yuhui Huang;Jianping Yuan;Elda Righi;Walid S. Kamoun.
Proceedings of the National Academy of Sciences of the United States of America (2012)
Biomarkers of response and resistance to antiangiogenic therapy.
Rakesh K. Jain;Dan G. Duda;Christopher G. Willett;Dushyant V. Sahani.
Nature Reviews Clinical Oncology (2009)
Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study
Christopher G. Willett;Dan G. Duda;Emmanuelle di Tomaso;Yves Boucher.
Journal of Clinical Oncology (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: